Medexus Pharmaceuticals (MDP) Competitors

Organigram (TSE:OGI) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Which has better valuation and earnings, OGI or MDP?

Medexus Pharmaceuticals has lower revenue, but higher earnings than Organigram. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$223.82M	1.45	-C$57.23M	C$0.01	202.50
Medexus Pharmaceuticals	C$105.66M	0.91	C$3.26M	C$0.02	148.50

Does the media prefer OGI or MDP?

In the previous week, Organigram's average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Organigram	Neutral
Medexus Pharmaceuticals	Neutral

Do insiders and institutionals believe in OGI or MDP?

4.1% of Organigram shares are held by institutional investors. Comparatively, 0.7% of Medexus Pharmaceuticals shares are held by institutional investors. 31.3% of Organigram shares are held by company insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts prefer OGI or MDP?

Organigram currently has a consensus target price of C$3.33, indicating a potential upside of 36.83%. Medexus Pharmaceuticals has a consensus target price of C$5.49, indicating a potential upside of 84.76%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Organigram.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Medexus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	4 Strong Buy rating(s)	3.29

Which has more volatility and risk, OGI or MDP?

Organigram has a beta of 2.077228, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 2.548292, suggesting that its stock price is 155% more volatile than the S&P 500.

Is OGI or MDP more profitable?

Medexus Pharmaceuticals has a net margin of 3.25% compared to Organigram's net margin of -31.69%. Medexus Pharmaceuticals' return on equity of 11.07% beat Organigram's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	-31.69%	-17.59%	-5.56%
Medexus Pharmaceuticals	3.25%	11.07%	4.89%

Summary

Medexus Pharmaceuticals beats Organigram on 9 of the 14 factors compared between the two stocks.